pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma

Response rates to conventional chemotherapeutics remain unsatisfactory for hepatocellular carcinoma (HCC) due to the high rates of chemoresistance and recurrence. Tumor-initiating cancer stem-like cells (CSLCs) are refractory to chemotherapy, and their enrichment leads to subsequent development of chemoresistance and recurrence. To overcome the chemoresistance and stemness in HCC, we synthesized a Pt nanocluster assembly (Pt-NA) composed of assembled Pt nanoclusters incorporating a pH-sensitive polymer and HCC-targeting peptide. Pt-NA is latent in peripheral blood, readily targets disseminated HCC CSLCs, and disassembles into small Pt nanoclusters in acidic subcellular compartments, eventually inducing damage to DNA. Furthermore, treatment with Pt-NA downregulates a multitude of genes that are vital for the proliferation of HCC. Importantly, CD24+ side population (SP) CSLCs that are resistant to cisplatin are sensitive to Pt-NA, demonstrating the immense potential of Pt-NA for treating chemoresistant HCC.

[1]  Ian D. McGilvray,et al.  Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Jacek K. Stolarczyk,et al.  Nanoparticle Clusters: Assembly and Control Over Internal Order, Current Capabilities, and Future Potential , 2016, Advanced materials.

[3]  Jun Wang,et al.  Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy , 2016, Proceedings of the National Academy of Sciences.

[4]  N. Chandrasekaran,et al.  DNA damage and mitochondria-mediated apoptosis of A549 lung carcinoma cells induced by biosynthesised silver and platinum nanoparticles , 2016 .

[5]  Warren C. W. Chan,et al.  DNA-controlled dynamic colloidal nanoparticle systems for mediating cellular interaction , 2016, Science.

[6]  V. Rotello,et al.  Highlights from the latest articles in nanomaterial-based therapies for targeting cancer stem cells. , 2015, Nanomedicine.

[7]  M. Makuuchi,et al.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Oncology.

[8]  K. Hui,et al.  EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma. , 2015, Journal of hepatology.

[9]  Xuesi Chen,et al.  Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Yi Yan Yang,et al.  Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells. , 2015, Nanomedicine.

[11]  Youqing Shen,et al.  Integration of Nanoassembly Functions for an Effective Delivery Cascade for Cancer Drugs , 2014, Advanced materials.

[12]  Taeghwan Hyeon,et al.  pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. , 2014, ACS nano.

[13]  C. Che,et al.  Controlled‐Release Systems for Metal‐Based Nanomedicine: Encapsulated/Self‐Assembled Nanoparticles of Anticancer Gold(III)/Platinum(II) Complexes and Antimicrobial Silver Nanoparticles , 2014, Advanced materials.

[14]  Taeghwan Hyeon,et al.  Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. , 2014, Journal of the American Chemical Society.

[15]  T. Hyeon,et al.  Cancer imaging: Lighting up tumours. , 2014, Nature materials.

[16]  T. Hyeon,et al.  Synthesis, Characterization, and Application of Ultrasmall Nanoparticles , 2014 .

[17]  M. Gottesman,et al.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. , 2013, ACS nano.

[18]  Wan-Ching Chiu,et al.  Caged Pt Nanoclusters Exhibiting Corrodibility to Exert Tumor‐Inside Activation for Anticancer Chemotherapeutics , 2013, Advanced materials.

[19]  P. Sadler,et al.  Challenges for metals in medicine: how nanotechnology may help to shape the future. , 2013, ACS nano.

[20]  Warren C W Chan,et al.  A plasmonic DNAzyme strategy for point-of-care genetic detection of infectious pathogens. , 2013, Angewandte Chemie.

[21]  Marcia Simon,et al.  Platinum folate nanoparticles toxicity: cancer vs. normal cells. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[22]  R. Deberardinis,et al.  A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals , 2013 .

[23]  Joseph W. Nichols,et al.  Odyssey of a cancer nanoparticle: from injection site to site of action. , 2012, Nano today.

[24]  A. Covey,et al.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma , 2012, CA: a cancer journal for clinicians.

[25]  Mingsheng Wang,et al.  Magnetic assembly route to colloidal responsive photonic nanostructures. , 2012, Accounts of chemical research.

[26]  Subinoy Rana,et al.  Surface functionalization of nanoparticles for nanomedicine. , 2012, Chemical Society reviews.

[27]  Bing Xu,et al.  Magnetic nanoparticles for the manipulation of proteins and cells. , 2012, Chemical Society reviews.

[28]  G. Feng.  Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. , 2012, Cancer cell.

[29]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .

[30]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[31]  S. Thorgeirsson,et al.  Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways , 2011, Hepatology.

[32]  I. Ng,et al.  CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. , 2011, Cell stem cell.

[33]  Shiladitya Sengupta,et al.  Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy , 2011, Nanotechnology.

[34]  Mark B. Carter,et al.  The Targeted Delivery of Multicomponent Cargos to Cancer Cells via Nanoporous Particle-Supported Lipid Bilayers , 2011, Nature materials.

[35]  I. Yagi,et al.  Study of Platinum Dissolution Mechanism Using a Highly Sensitive Electrochemical Quartz Crystal Microbalance , 2011 .

[36]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[37]  Dietrich Büsselberg,et al.  Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects , 2011, Cancers.

[38]  S. Niclou,et al.  Critical appraisal of the side population assay in stem cell and cancer stem cell research. , 2011, Cell stem cell.

[39]  Betty Y. S. Kim,et al.  Current concepts: Nanomedicine , 2010 .

[40]  S. Valiyaveettil,et al.  Active targeting of cancer cells using folic acid-conjugated platinum nanoparticles. , 2010, Nanoscale.

[41]  P. Donahoe,et al.  Müllerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics , 2010, Proceedings of the National Academy of Sciences.

[42]  Katsumi Kobayashi,et al.  Platinum nanoparticles: a promising material for future cancer therapy? , 2010, Nanotechnology.

[43]  Suresh Valiyaveettil,et al.  DNA damage and p53-mediated growth arrest in human cells treated with platinum nanoparticles. , 2010, Nanomedicine.

[44]  E. Kumacheva,et al.  Properties and emerging applications of self-assembled structures made from inorganic nanoparticles. , 2010, Nature nanotechnology.

[45]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[46]  Xiaohu Gao,et al.  Plasmonic fluorescent quantum dots. , 2009, Nature nanotechnology.

[47]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[48]  Parag Aggarwal,et al.  Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[49]  Stefan Bräse,et al.  Cellular uptake of platinum nanoparticles in human colon carcinoma cells and their impact on cellular redox systems and DNA integrity. , 2009, Chemical research in toxicology.

[50]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[51]  S. Sortino,et al.  Nitric oxide photocaging platinum nanoparticles with anticancer potential , 2008 .

[52]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[53]  Donhee Ham,et al.  Chip–NMR biosensor for detection and molecular analysis of cells , 2008, Nature Medicine.

[54]  Shuming Nie,et al.  Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. , 2008, Journal of the American Chemical Society.

[55]  W. Stark,et al.  Micro-organism-triggered release of silver nanoparticles from biodegradable oxide carriers allows preparation of self-sterilizing polymer surfaces. , 2008, Small.

[56]  P. Dröge,et al.  Site selectivity of platinum anticancer therapeutics. , 2008, Nature chemical biology.

[57]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[58]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[59]  Bing Xu,et al.  FePt@CoS(2) yolk-shell nanocrystals as a potent agent to kill HeLa cells. , 2007, Journal of the American Chemical Society.

[60]  Ayusman Sen,et al.  Silver bromide nanoparticle/polymer composites: dual action tunable antimicrobial materials. , 2006, Journal of the American Chemical Society.

[61]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[62]  Chad A Mirkin,et al.  Nanostructures in biodiagnostics. , 2005, Chemical reviews.

[63]  D. Martin,et al.  Nanomedicine , 2005, BMJ.

[64]  S. Urien,et al.  Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients , 2004, Cancer Chemotherapy and Pharmacology.

[65]  Hans-Peter Lipp,et al.  Toxicity of platinum compounds , 2003, Expert opinion on pharmacotherapy.

[66]  A Bravin,et al.  Lack of Cell Death Enhancement after Irradiation with Monochromatic Synchrotron X Rays at the K-Shell Edge of Platinum Incorporated in Living SQ20B Human Cells as cis-Diamminedichloroplatinum (II) , 2002, Radiation research.

[67]  C. Mirkin,et al.  Scanometric DNA array detection with nanoparticle probes. , 2000, Science.

[68]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[69]  S. Lippard,et al.  In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. , 1985, Biochemistry.

[70]  H. Pinedo,et al.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. , 1984, Cancer treatment reports.

[71]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .